Ilomedin

Iloprost Trometamol, the active ingredient in Ilomedin, is a prostacyclin analog presented as a solution for injection for intravenous use. It treats pulmonary arterial hypertension and digital ulcers associated with systemic sclerosis in adult patients. Ilomedin is authorized in the European Union and is supplied as a sterile injectable solution.

GNH USA supplies Ilomedin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Ilomedin is a prostacyclin analog that acts on the pulmonary vascular pathway to provide vasodilation and improve microcirculation.

Pulmonary arterial hypertension: improves functional class, exercise capacity and hemodynamic parameters. Digital ulcers associated with systemic sclerosis: accelerates ulcer healing and reduces the formation of new ulcers. Raynaud's phenomenon: decreases frequency and severity of vasospastic attacks.

Ilomedin may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Headache - Flushing - Nausea - Jaw pain or discomfort

Serious or Rare Side Effects: - Severe hypotension - Pulmonary edema - Clinically significant bleeding events

When using Ilomedin, clinicians should consider several safety measures.

Monitor blood pressure: watch for hypotensive episodes during and after infusion. Avoid use in recent major hemorrhage: increased bleeding risk. Caution in heart failure: may exacerbate fluid overload. Adjust in renal impairment: dose titration may be required. Contraindicated in known hypersensitivity to iloprost or formulation components. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ilomedin can interact with other medicines that affect vascular tone or coagulation.

Major Interactions (Avoid): - Concomitant nitrates or other potent vasodilators: risk of severe hypotension. - Anticoagulants (e.g., warfarin, heparin): heightened bleeding tendency. - Phosphodiesterase‑5 inhibitors: additive vasodilatory effect.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: may modestly lower blood pressure. - Beta‑blockers: can mask tachycardia associated with hypotension. - NSAIDs: may affect renal function and fluid balance.